Technology
Health
Biotechnology
Leap Therapeutics
$2.029876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.11 (-5.40%) Today
+$0.00 (0.25%) After Hours
Why Robinhood?
You can buy or sell LPTX and other stocks, options, ETFs, and crypto commission-free!
About
Leap Therapeutics, Inc. Common Stock, also called Leap Therapeutics, is a clinical stage biopharmaceutical company. Read More It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics. The firm's pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Employees
22
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
31.32M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
288.07K
High Today
$2.25
Low Today
$1.89
Open Price
$2.16
Volume
837.27K
52 Week High
$10.25
52 Week Low
$1.35
Collections
Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
2017 IPO
News
Yahoo FinanceMar 11
Four Tech Stocks Setting The Pace On Monday
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The success of the tech stock market is directly correlated to the operating assumption that tech companies are prepared to meet the rising challenges presently facing society.
PR NewswireMar 8
Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer
CAMBRIDGE, Mass., March 8, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer, being held March 16-19, 2019 in Honolulu, HI. About the DKN-01 P204 clinical trial The P204 study is a Phase 2 basket study of DKN-01 as both a monotherapy and in combination with paclitaxel in patients with ...
Price Paid on Robinhood
20% Lower
Right Now
52 Week Low
$1.35
Average Price Paid
$2.52
52 Week High
$10.25
Earnings
-$0.85
-$0.71
-$0.58
-$0.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.57 per share
Actual
Expected Today, Pre-Market